CALT: AI 评分 46/100 — AI 分析 (4月 2026)

概要：

CALT是做什么的？

CALT的投资论点是什么？

CALT在哪个行业运营？

CALT有哪些增长机遇？

• Expansion of Nefecon's Market Share: Nefecon, approved for IgAN, has the potential to capture a larger share of the market through increased awareness, expanded geographic reach, and favorable reimbursement policies. The IgAN market is estimated to grow to $2.5 billion by 2028. Calliditas can leverage its existing sales and marketing infrastructure to drive adoption among nephrologists and patients. Successful post-market studies demonstrating long-term efficacy and safety could further solidify Nefecon's position as a leading treatment option.
• Successful Clinical Development of Setanaxib: Setanaxib, a NOX inhibitor, is currently in Phase 2b/3 clinical trials for primary biliary cholangitis (PBC) and Phase 2 clinical trials for other indications. Positive clinical trial results could lead to regulatory approvals and commercialization in multiple markets, significantly expanding Calliditas's revenue base. The PBC market is projected to reach $1.2 billion by 2027. Setanaxib's potential to address multiple fibrotic diseases represents a substantial growth opportunity.
• Strategic Partnerships and Acquisitions: Calliditas can pursue strategic partnerships and acquisitions to expand its pipeline, access new technologies, and enter new markets. Collaborations with other biotechnology companies or research institutions could accelerate drug development and reduce risk. Acquiring complementary assets or companies could broaden Calliditas's therapeutic focus and create synergies. The company has the financial resources to pursue such opportunities, given its market capitalization of $2.15 billion.
• Geographic Expansion: Calliditas currently operates primarily in Europe and North America. Expanding into new geographic markets, such as Asia and Latin America, could drive revenue growth and diversify the company's revenue streams. These markets represent significant opportunities due to their large patient populations and increasing healthcare spending. However, Calliditas would need to navigate regulatory hurdles and establish local partnerships to succeed in these markets. The timeline for expansion would depend on regulatory approvals and market access strategies.
• Development of Budenofalk for Autoimmune Hepatitis: Calliditas is developing Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. Successful clinical development and regulatory approval could provide another revenue stream and expand Calliditas's therapeutic focus. The autoimmune hepatitis market is estimated to grow to $800 million by 2026. Budenofalk's potential to address this unmet medical need represents a valuable growth opportunity for Calliditas.

• Market capitalization of $2.15 billion reflects investor confidence in Calliditas's pipeline and commercial prospects.
• Gross margin of 93.6% indicates strong pricing power and efficient manufacturing processes.
• Nefecon approval and commercialization provide a revenue stream and validation of the company's drug development capabilities.
• Ongoing Phase 2b/3 clinical trial for Setanaxib in primary biliary cholangitis represents a significant potential growth catalyst.
• Operating in the orphan drug market allows for premium pricing and reduced competition compared to larger pharmaceutical markets.

CALT提供哪些产品和服务？

• Develop and commercialize pharmaceutical products for orphan indications.
• Focus on renal and hepatic diseases.
• Offer Nefecon for the treatment of immunoglobulin A nephropathy (IgAN).
• Develop Setanaxib, a NOX inhibitor, for primary biliary cholangitis (PBC) and other indications.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Seek regulatory approvals from agencies like the FDA and EMA.
• Market and sell their approved products to healthcare providers and patients.

CALT如何赚钱？

• Develop and patent novel pharmaceutical products.
• Conduct clinical trials to demonstrate safety and efficacy.
• Obtain regulatory approvals to market and sell their products.
• Generate revenue through product sales.
• Partner with other companies for development and commercialization.

• Patients with orphan renal and hepatic diseases.
• Nephrologists and hepatologists who treat these patients.
• Hospitals and clinics that provide care for these patients.
• Pharmacies that dispense their medications.

• Patent protection for their drug candidates.
• Regulatory exclusivity for orphan drugs.
• Specialized expertise in renal and hepatic diseases.
• Established relationships with key opinion leaders in the medical community.

什么因素可能推动CALT股价上涨？

• Upcoming: Phase 2b/3 clinical trial results for Setanaxib in primary biliary cholangitis (PBC) expected by late 2026.
• Ongoing: Continued commercialization and market penetration of Nefecon for IgAN.
• Ongoing: Potential expansion of Nefecon's label to include additional patient populations.
• Upcoming: Regulatory submissions for Setanaxib in various indications.

CALT的主要风险是什么？

• Potential: Clinical trial failures for Setanaxib or other pipeline candidates.
• Potential: Regulatory delays or rejections for new drug applications.
• Ongoing: Competition from other companies developing treatments for renal and hepatic diseases.
• Ongoing: Changes in reimbursement policies that could impact the pricing and market access of their products.
• Potential: Product liability claims or recalls.

CALT的核心优势是什么？

• Approved product (Nefecon) generating revenue.
• Promising pipeline candidate (Setanaxib) with multiple indications.
• High gross margin (93.6%).
• Focus on orphan diseases with unmet medical needs.

CALT的劣势是什么？

• Negative profit margin (-38.6%).
• Reliance on a limited number of products.
• High R&D expenses.
• Dependence on clinical trial outcomes.

CALT有哪些机遇？

• Expansion of Nefecon's market share.
• Successful clinical development of Setanaxib.
• Strategic partnerships and acquisitions.
• Geographic expansion into new markets.

CALT面临哪些威胁？

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other companies.
• Changes in reimbursement policies.

CALT的竞争对手是谁？

• Amag Pharmaceuticals — Focuses on women's health and rare diseases. — (AMAM)
• Blueprint Medicines — Develops kinase inhibitors for cancer and rare diseases. — (BLU)
• Deciphera Pharmaceuticals — Develops kinase inhibitors for cancer. — (DCPH)
• DICE Therapeutics — Develops oral therapeutics to treat chronic diseases in immunology. — (DICE)
• Fusion Pharmaceuticals — Develops radiopharmaceuticals for cancer treatment. — (FUSN)

Key Metrics

• MoonshotScore: 46/100

Company Profile

• CEO: Renee Aguiar-Lucander
• Headquarters: Stockholm, SE
• Employees: 222
• Founded: 2020

AI Insight

• ADR Level: 2
• ADR Ratio: 1:1